Agilent Technologies Inc introduces the Agilent Seahorse XF HS Miniplate designed specifically for the Agilent Seahorse XF HS Mini Analyser for improved immune cell metabolic analysis.

The XF HS Mini is the latest addition to Agilent’s range of Seahorse XF platforms, which analyse mitochondrial respiration, glycolysis, and ATP production in live cells, in real-time. These metabolic measurements enable researchers to better understand cell health, function, and signalling.

The highly sensitive XF HS Mini analyser offers improved performance and precision, requiring fewer cells per well, an improved more consistent suspension cell workflow, and streamlined analytics. These improvements enable researchers to confidently generate XF data from quantity limited or low respiring cell types, such as immune cells, where measurements were previously not possible.

“Our cells are highly manipulated immune cells which are short-lived, costly, and labour-intensive to generate. Obtaining higher-sensitivity with fewer cell numbers is the ‘make or break’ that enables us to use Agilent’s Seahorse XF technology in our disease model,” stated Katja Weinacht, Assistant Professor of Paediatrics, Division of Stem Cell Transplantation and Regenerative Medicine, Stanford University.

“As our customers strive to unlock biology in more complex and specialised in vivo settings, the need to interrogate rarer cell populations has become evident,” stated David Ferrick, Senior Director, Agilent’s Cell Analysis Division. “The improved sensitivity and precision of the XF HS Mini will open up this new world of metabolic analysis for these customers.”